BioTuesdays

Author - Leonard Zehr

Feature

In conversation with Kevin Smith

As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and executing the company’s global...

December 15, 2015
Titan Pharmaceuticals Logo
Developments

FDA panel to review NDA for Probuphine

The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...

December 9, 2015
ciclofilin pharma
Developments

Ciclofilin Pharma forms liver disease SAB

Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...

December 3, 2015
Feature

Oramed sees value creating events through 2016

By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for...

December 1, 2015
Can-Fite Logo
Markets

HCW ups Can-Fite BioPharma price target to $6

H.C. Wainwright has raised its price target on “buy-rated” Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) to $6 from $4. The stock closed at $3.23 on Friday. “In our view, the company’s piclidenoson programs remain the...

November 30, 2015